X

Trial Profile

Clinical trial of MGCD 265 in patients with Axl-positive non-small cell lung cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glesatinib (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Sponsors MethylGene

Most Recent Events

09 Mar 2016 In Sept 2015, results of this trial were presented at the World Conference on Lung Cancer 2015, as per Mirati Therapeutics media release.
11 Sep 2015 According to a Mirati Therapeutics media release, the results from first non-small cell lung cancer patient with AXL gene amplification enrolled in the phase 1b expansion cohort will be presented at the Association of Lung Cancer (IASLC) 16th World Conference on Lung Cancer.
11 Mar 2015 Status changed from not yet recruiting to recruiting, based on information in a Mirati Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com